Constipation

Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management

Growing evidence suggests an increasing significance for the extent of gastrointestinal tract (GIT) dysfunction in Parkinson’s disease (PD). Most patients suffer from GIT symptoms, including dysphagia, sialorrhea, bloating, nausea, vomiting, gastroparesis, and constipation during the disease course. The underlying pathomechanisms of this α-synucleinopathy play an important role in disease development and progression, i.e., early accumulation […]

Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management Read More »

Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS

The recent revelation that the gut microbiome, home to approximately 100 trillion microorganisms, is implicated in the development of both health and disease has spurred an exponential increase in interdisciplinary research involving gut microbiology. In all this hype, there is a need to better understand and contextualize the emerging evidence for the role of the gut microbiota in

Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS Read More »

Gastrointestinal Microbiome and Neurologic Injury

: Communication between the enteric nervous system (ENS) of the gastrointestinal (GI)tract and the central nervous system (CNS) is vital for maintaining systemic homeostasis. Intrinsicand extrinsic neurological inputs of the gut regulate blood flow, peristalsis, hormone release, andimmunological function. The health of the gut microbiome plays a vital role in regulating the overallfunction and well-being

Gastrointestinal Microbiome and Neurologic Injury Read More »

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients

Background and Objectives: Short-chain fatty acids (SCFAs) are gut microbial metabolitesthat promote the disease process in a rodent model of Parkinson’s disease (PD), but fecallevels of SCFAs in PD patients are reduced. Simultaneous assessments of fecal and plasmaSCFA levels, and their inter-relationships with the PD disease process are scarce. We aimedto compare fecal and plasma

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients Read More »

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease

Braak’s hypothesis has been extremely influential over the last two decades. However, neuropathological and clinical evidence suggest that the model does not conform to all patients with Parkinson’s disease (PD). To resolve this controversy, a new model was recently proposed; in brain-first PD, the initial α-synuclein pathology arise inside the central nervous system, likely rostral to

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease Read More »

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation

A variety of opinions exist on the potential of probiotics to provide relief from chronic constipation with much focus placed on their mechanism of action and causes of heterogeneity in the results of different studies. We aimed to determine the efficacy and safety of ingesting Bifidobacterium bifidum (B. bifidum) CCFM16 for 28 days to relieve

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation Read More »

Non-Motor Symptoms and Their Associated Factors in Parkinson’s Disease

Background: Parkinson’s disease is a common neurologic ailment that causes tremor and bradykinesia. The prevalenceof Parkinson’s disease is estimated to be 1–2 in 1000, affecting about 1% of the population over the age of 60 years. Theobjective of this study was to find the frequency of Non-Motor Symptoms in patients with Parkinson’s Disease (PD) andits

Non-Motor Symptoms and Their Associated Factors in Parkinson’s Disease Read More »

Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson’s disease

Two hallmarks of Parkinson’s disease (PD) are the widespread deposition of misfolded alpha-synuclein (αSyn) protein in the nervous system and loss of substantia nigra dopamine neurons. Recent research has suggested that αSyn aggregates in the enteric nervous system (ENS) lead to prodromal gastrointestinal (GI) symptoms such as constipation in PD, then propagating to the brain stem and eventually triggering neurodegeneration and

Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson’s disease Read More »

The Undeniable Link Between the Brain and Gut

Nausea, heartburn, indigestion, constipation, andstomach pain are all kinds of gastrointestinal problems we have faced before. They are easy to dismissas merely an upset stomach, but this mentality couldbuild up and ultimately be detrimental to mental and physicalhealth. Improperly caring for the digestive system can lead toextensive intestinal health issues. The microbiome is a collectionof

The Undeniable Link Between the Brain and Gut Read More »

The Emerging Scenario of the Gut–Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases

The fact that millions of people worldwide suffer from Alzheimer’s disease (AD) orParkinson’s disease (PD), the two most prevalent neurodegenerative diseases (NDs), has beena permanent challenge to science. New tools were developed over the past two decades andwere immediately incorporated into routines in many laboratories, but the most valuable scientificcontribution was the “waking up” of

The Emerging Scenario of the Gut–Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases Read More »